A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 4, 2003, Pages 977-990

  Ferguson, Neil M ^a   Mallett, Susan ^b   Jackson, Helen ^c   Roberts, Noel ^c   Ward, Penelope ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UK COCHRANE CENTRE   (United Kingdom)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE DERIVATIVE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR;

ADULT; AGE DISTRIBUTION; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CLINICAL STUDY; COMMUNICABLE DISEASE; CONTROLLED STUDY; DISEASE SIMULATION; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; HEALTH SURVEY; HUMAN; IMMUNITY; INCIDENCE; INFANT; INFECTION PREVENTION; INFECTION RATE; INFLUENZA; INFLUENZA VIRUS; MATHEMATICAL MODEL; NONHUMAN; NURSING HOME; POPULATION DYNAMICS; POPULATION STRUCTURE; PREDICTION; SEASONAL VARIATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALGORITHMS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; FORECASTING; HUMANS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MODELS, STATISTICAL; ORTHOMYXOVIRIDAE; POPULATION;

EID: 0037397232     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg136     Document Type: Article

References (58)

1. Simonsen, L., Clarke, M. J., Williamson, G. D., Stroup, D. F., Arden, N. H. & Schonberger, L. B. (1997). The impact of influenza epidemics on mortality: introducing a severity index. American Journal of Public Health 87, 1944-50.
2. Armstrong, G. L., Conn, L. A. & Pinner, R. W. (1999). Trends in infectious disease mortality in the United States during the 20th century. Journal of the American Medical Association 281, 61-6.
3. Sullivan, K. M., Monto, A. S. & Longini, I. M. (1993). Estimates of the US health impact of influenza. American Journal of Public Health 83, 1712-6.
4. Oxford, J. S. (2000). Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology. Reviews in Medical Virology 10, 119-33.
5. Meltzer, M. I., Cox, N. J. & Fukuda, K. (1999). The economic impact of pandemic influenza in the United States: priorities for intervention. Emerging Infectious Diseases 5, 659-71.
6. Monto, A. S. & Ohmit, S. E. (1996). Effectiveness evaluation of inactivated influenza vaccines: methods and results. In Options for the Control of Influenza (Brown, L. E. Hampson, A. W. & Webster, R. G., Eds), pp. 93-6. Elsevier Science, Amsterdam, The Netherlands.
7. Lipsitch, M., Bergstrom, C. T. & Levin, B. R. (2000). The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proceedings of the National Academy of Sciences, USA 97, 1938-43.
8. Austin, D. J., Bonten, M. J. M., Weinstein, R. A., Slaughter, S. & Anderson, R. M. (1999). Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proceedings of the National Academy of Sciences, USA 96, 6908-13.
9. Blower, S. M., Porco, T. C. & Darby, G. (1998). Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nature Medicine 4, 673-8.
10. Stilianakis, N. I., Boucher, C. A. B., DeJong, M. D., Van-Leeuwen, R., Schuurman, R. & DeBoer, R. J. (1997). Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model. Journal of Virology 71, 161-8.
11. Ribeiro, R. M. & Bonhoeffer, S. (2000). Production of resistant HIV mutants during antiretroviral therapy. Proceedings of the National Academy of Sciences, USA 97, 7681-6.
12. Stilianakis, N. I., Perelson, A. S. & Hayden, F. G. (1998). Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. Journal of Infectious Diseases 177, 863-73.
13. Tisdale, M. (2000). Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Reviews in Medical Virology 10, 45-55.
14. Carr, J., Herlocher, L., Elias, S., Harrison, S., Gibson, V., Clark, L. et al. (2001). Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. In Program and Abstracts of the Fourteenth International Conference on Antiviral Research, Seattle, WA, USA, 2001. Abstract 162, p. 85. International Society for Antiviral Research (http://www.isar-icar.com/).
15. Barker, W. H., Raubertas, R., Menegus, M., Obrien, D., Freundlich, C. & Betts, R. (1993). Case-control study of influenza vaccine prevention of pneumonia hospitalization among older persons 1989-1992. American Journal of Epidemiology 138, 624.
16. Tillett, H. E., Smith, J. W. G. & Gooch, C. D. (1983). Excess deaths attributable to influenza in England and Wales - age at death and certified cause. International of Epidemiology 12, 344-52.
17. Simonsen, L., Fukuda, K., Schonberger, L. B. & Cox, N. J. (2000). The impact of influenza epidemics on hospitalizations. Journal of Infectious Diseases 181, 831-7.
18. Simonsen, L. (1999). The global impact of influenza on morbidity and mortality. Vaccine 17, S3-10.
19. Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D. et al. (2000). Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. Journal of the American Medical Association 283, 1016-24.
20. Hayden, F. G., Treanor, J. J., Betts, R. F., Lobo, M., Esinhart, J. D. & Hussey, E. K. (1996). Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. Journal of the American Medical Association 275, 295-9.
21. Hayden, F. G., Fritz, R., Lobo, M. C., Alvord, W., Strober, W. & Straus, S. E. (1998). Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. Journal of Clinical Investigation 101, 643-9.
22. Hayden, F. G., Treanor, J. J., Fritz, R. S., Lobo, M., Betts, R. F., Miller, M. et al. (1999). Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. Journal of the American Medical Association 282, 1240-6.
23. Mann, P. G., Pereira, M. S., Smith, J. W., Hart, R. J. & Williams, W. O. (1981). A five-year study of influenza in families. Journal of Hygiene 87, 191-200.
24. Fox, J. P., Cooney, M. K., Hall, C. E. & Foy, H. M. (1982). Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. American Journal of Epidemiology 116, 228-42.
25. Grenfell, B. T. & Anderson, R. M. (1985). The estimation of age-related rates of infection from case notifications and serological data. Journal of Hygiene 95, 419-36.
26. Ferguson, N. M., Anderson, R. M. & Garnett, G. P. (1996). Mass vaccination to control chickenpox: the influence of zoster. Proceedings of the National Academy of Sciences, USA 93, 7231-5.
27. Ferguson, N. M., Nokes, D. J. & Anderson, R. M. (1996). Dynamical complexity in age-structured models of the transmission of the measles virus: epidemiological implications at high levels of vaccine uptake. Mathematical Biosciences 138, 101-30.
28. Babad, H. R., Nokes, D. J., Gay, N. J., Miller, E., Morgan-Caper, P. & Anderson, R. M. (1995). Predicting the impact of measles vaccination in England and Wales: model validation and analysis of policy options. Epidemiology and Infection 114, 319-44.
29. Schenzle, D. (1984). An age-structured model of pre- and post-vaccination measles transmission. IMA Journal of Mathematics Applied in Medicine and Biology 1, 169-91.
30. Fox, J. P., Hall, C. E., Cooney, M. K. & Foy, H. M. (1982). Influenza virus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. American Journal of Epidemiology 116, 212-27.
31. Osterhaus, A. D. M. E., Oxford, J. S., Jackson, H. & Ward, P. (2000). Age related differences in virus titers in patients in influenza trials of oseltamivir, a novel oral influenza therapy. In Program and Abstracts of the Thirteenth International Conference on Antiviral Research, Baltimore, MD, USA, 2000. Abstract 64, p. 54, International Society for Antiviral Research (http://www.isar-icar.com/).
32. Fries, L. F., Dillon, S. B., Hildreth, J. E., Karron, R. A., Funkhouser, A. W., Friedman, C. J. et al. (1993). Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge. Journal of Infectious Diseases 167, 593-601.
33. Frank, A. L., Taber, L. H. & Wells, J. M. (1983), Individuals infected with two subtypes of influenza A virus in the same season. Journal of Infectious Diseases 147, 120-4.
34. Haaheim, L. R. & Flugsrud, L. B. (1993). Fifteen years of routine serosurveillance in Norway. In Options for the Control of Influenza II (Hannoun, C., Ed.), vol. II, pp. 353-8. Elsevier Science, Amsterdam, The Netherlands.
35. Monto, A. S. & Kioumehr, F. (1975). The Tecumseh Study of Respiratory Illness. IX: occurrence of influenza in the community, 1966-1971. American Journal of Epidemiology 102, 553-63.
36. Glezen, W. P. (1996). Emerging infections: pandemic influenza. Epidemiological Reviews 18, 64-76.
37. Hope-Simpson, R. E. (1984). Age and secular distributions of virus-proven influenza patients in successive epidemics 1961-1976 in Cirencester: epidemiological significance discussed. Journal of Hygiene 92, 303-36.
38. Public Health Laboratory Service. (2002). Influenza Disease Facts [Online.] http://www.phls.org.uk/topics_az/influenza/ data⋯nu.htm (14 February 2003, date last accessed).
39. Fleming, D. M., Zambon, M. C., Bartfields. A. I. M. & Jong, J. C. (1999). The duration and magnitude of influenza epidemics: a study of surveillance data from sentinel general practices in England, Wales and the Netherlands. European Journal of Epidemiology 15, 467-73.
40. Hope-Simpson, R. E. (1981). The role of season in the epidemiology of influenza. Journal of Hygiene 86, 35-47.
41. Frank, A. L., Taber, L. H. & Porter, C. M. (1987). Influenza B virus reinfection. American Journal of Epidemiology 125, 576-86.
42. Gubareva, L. V., Matrosovich, M. N., Brenner, M. K., Bethell, R. C. & Webster, R. G. (1998). Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. Journal of Infectious Diseases 178, 1257-62.
43. Tai, C. Y., Escarpe, P. A., Sidwell, R. W., Williams, M. A., Sew, W., Wu, H. et al. (1998). Characterisation of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS4071. Antimicrobial Agents and Chemotherapy 42, 3234-41.
44. Jackson, H. C., Roberts, N., Wang, Z. M. & Belshe, R. (2000). Management of influenza: use of new antivirals and resistance in perspective. Clinical Drug Investigation 20, 447-54.
45. Stilianakis, N. I., Perelson, A. S. & Hayden, F. G. (2002). Drug resistance and influenza pandemics. Lancet 359, 1862-3.
46. Centres for Disease Control, USA. (2001). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 50, 1-46.
47. Bernstein, E., Kaye, D., Abrutyn, E., Gross, P., Dorfman, M. & Murasko, D. M. (1999). Immune response to influenza vaccination in a large healthy elderly population. Vaccine 17, 82-94.
48. Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995), The efficacy of influenza vaccine in elderly persons - a metaanalysis and review of the literature. Annals of Internal Medicine 123, 518-27.
49. Peters, P. H., Gravenstein, S., Norwood, P., De Bock, V., Van Couter, A., Gibbens, M. et al. (2001). Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. Journal of the American Geriatrics Society 49, 1025-31.
50. Hayden, F. G., Serber, S. G., Belshe, R. B., Clover, R. D., Hay, A. J. & Pyke, S. (1991). Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrobial Agents and Chemotherapy 35, 1741-7.
51. Hayden, F. G., Belshe, R. B., Clover, R. D., Hay, A. J., Oakes, M. G. & Soo W. (1989). Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. New England Journal of Medicine 321, 1696-702.
52. Hall, C. B., Dolin, R., Gala, C. L., Markovitz, D. M., Zhang, Y. Q., Madore, P. H. et al. (1987). Children with influenza A infection: treatment with rimantidine. Pediatrics 80, 275-82.
53. Sweet, C., Hayden, F. G., Jakeman, K. J., Grambas, S. & Hay, A. J. (1991). Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. Journal of Infectious Diseases 164, 969-72.
54. Bean, W. J., Threlkeld, S. C. & Webster, R. G. (1989). Biologic potential of amantadine-resistant influenza A virus in an avian model. Journal of Infectious Diseases 159, 1050-6.
55. Lubeck, M. D., Schulman, J. L. & Palese, P. (1978). Susceptibility of influenza A viruses to amantadine is influenced by the gene coding for M protein. Journal of Virology 28, 710-6.
56. Mast, E. E., Harmon, M. W., Gravenstein, S., Wu, S. P., Arden, N. H., Circo, R. et al. (1991). Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). American Journal of Epidemiology 134, 988-97.
57. Klimov, A. I., Rocha, E., Hayden, F. G., Shult, P. A., Roumillat, L. F. & Cox, N. J. (1995). Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. Journal of Infectious Diseases 172, 1352-5.
58. Englund, J. A., Champlin, R. E., Wyde, P. R., Kantarjian, H., Atmar, R. L., Tarrand, J. et al. (1998). Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clinical Infectious Diseases 26, 1418-24.